AbbVie Advances Two Novel B-Cell Lymphoma Therapies in First-in-Human Trials
核心洞察
AbbVie Deutschland GmbH & Co. KG is conducting two separate first-in-human Phase 1 studies evaluating ABBV-525, a MALT1 (搜索) inhibitor, and ABBV-101, a BTK (搜索) degrader, for relapsed/refractory B-cell non-Hodgkin's lymphoma (搜索).
ABBV-525 targets the MALT1 (搜索) protein that helps cancer cells survive and grow, while ABBV-101 represents a novel BTK (搜索) degrader approach that removes BTK proteins rather than simply inhibiting them.
The ABBV-525 study will enroll approximately 150 participants worldwide over 64 months, while the ABBV-101 study will include approximately 188 patients over 60 months.
AbbVie Deutschland GmbH & Co. KG has initiated two groundbreaking first-in-human clinical trials targeting relapsed/refractory B-cell non-Hodgkin's lymphoma (搜索) (NHL) with novel therapeutic approaches. The studies evaluate ABBV-525, a MALT1 (搜索) inhibitor, and ABBV-101, a BTK (搜索) degrader, representing innovative strategies to combat B-cell malignancies that have proven resistant to existing treatments.
ABBV-525: Targeting MALT1 Pathway
The multicenter ABBV-525 study focuses on participants with relapsed/refractory B-cell NHL, including chronic lymphocytic leukemia (搜索) (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (搜索) (DLBCL), follicular lymphoma (搜索) (FL), mantle cell lymphoma (搜索) (MCL), marginal zone lymphoma (搜索) (MZL), and Waldenstrom's Macroglobulinemia (搜索) (WM).
ABBV-525 functions as a MALT1 (搜索) inhibitor, targeting a protein that helps normal B cells grow but also enables cancer cells to survive and proliferate. By inhibiting or "blocking" MALT1, ABBV-525 may kill cancer cells or prevent their growth. The study drug, which has been evaluated in laboratory animals but never in humans, will be administered orally once daily to all participants.
The primary objectives include determining the safety and tolerability of ABBV-525, establishing an appropriate dose and schedule, understanding pharmacokinetic properties, evaluating efficacy in treating B-cell malignancies, and monitoring potential cardiac effects. Approximately 150 participants will be enrolled worldwide in this 64-month study.
ABBV-101: Novel BTK Degradation Approach
The Phase 1, open-label ABBV-101 study represents a paradigm shift in BTK (搜索)-targeted therapy. Unlike traditional BTK inhibitors, ABBV-101 belongs to a new class of drugs called BTK degraders that physically remove BTK proteins rather than simply blocking their function.
BTK (搜索) protein serves as a key component in normal B cell growth but also supports cancer cell survival and proliferation. The degrader mechanism of ABBV-101 may provide longer, more durable responses compared to current BTK inhibitor treatments by completely eliminating the target protein.
The study will enroll approximately 188 patients aged 18 or older with relapsed or refractory B-cell NHL. ABBV-101 will be administered once daily in tablet format for up to 60 months, continuing until disease progression, intolerable side effects, or patient/physician decision to discontinue.
Two-Phase Study Design
The ABBV-101 trial employs a structured two-part approach. Part 1 involves dose escalation, where patients are assigned to available dose levels based on enrollment timing. Safety monitoring prevents higher dose groups from enrolling until lower dose safety data is evaluated. Part 2 focuses on dose expansion, with patients receiving ABBV-101 at the dose level determined safe and effective in Part 1.
Addressing Unmet Medical Need
Both studies target a significant clinical challenge in B-cell malignancies. While treatments exist for patients with B-cell NHL, many experience disease relapse or fail to respond to current therapies. Non-Hodgkin's lymphoma develops when lymphocytes, white blood cells that are part of the immune system, grow uncontrollably. The heterogeneous nature of NHL, with different subtypes behaving differently based on cellular characteristics, necessitates diverse therapeutic approaches.
The development of these novel mechanisms—MALT1 (搜索) inhibition and BTK (搜索) degradation—represents AbbVie's commitment to addressing treatment-resistant B-cell malignancies through innovative targeted therapies that may overcome limitations of existing treatments.